EU/3/03/133

Table of contents

About

On 17 February 2003, orphan designation (EU/3/03/133) was granted by the European Commission to Jerini AG, Germany, for icatibant acetate for the treatment of angioedema.

In September 2013, Jerini AG changed name to Shire Orphan Therapies GmbH.

Icatibant acetate has been authorised in the EU as Firazyr since 11 July 2008.

The sponsorship was transferred to Shire Pharmaceuticals Ireland Limited, Ireland in September 2018.

Key facts

Active substance
icatibant acetate
Medicine name
Firazyr
Disease / condition
Treatment of angioedema
Date of first decision
18/02/2003
Outcome
Positive
EU designation number
EU/3/03/133

Sponsor's contact details

Shire Pharmaceuticals Ireland Limited
Block 2 & 3 Miesian Plaza
50 - 58 Baggot Street Lower
Dublin 2
Ireland
Tel. +353 1 6422161
E-mail: toro-cortes@shire.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating